Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-... Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-sized nanoparticles and have proprietary coatings. It has applied the AMPPLIFY technology to create nanosuspensions of loteprednol etabonate, or LE, acorticosteroid designed for ocular applications, resulting in two product candidates. INVELTYS was approved in August 2018 for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25 per cent is in Phase 3 development for the temporary relief of the signs and symptoms of dry eye disease. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.8 | -11.6788321168 | 6.85 | 7.0651 | 5.785 | 26022 | 6.44452449 | CS |
| 4 | -0.88 | -12.6984126984 | 6.93 | 7.9675 | 5.785 | 20985 | 6.91411166 | CS |
| 12 | -1.96 | -24.4694132335 | 8.01 | 11.2 | 5.785 | 56027 | 8.01340348 | CS |
| 26 | 0.65 | 12.037037037 | 5.4 | 11.2 | 4.95 | 41480 | 7.54329188 | CS |
| 52 | -1.95 | -24.375 | 8 | 11.2 | 4.21 | 84244 | 6.76636407 | CS |
| 156 | -64.95 | -91.4788732394 | 71 | 74 | 3.5444 | 570454 | 20.54956413 | CS |
| 260 | -365.45 | -98.3714670256 | 371.5 | 734 | 3.5444 | 1008816 | 199.21999868 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
